ASC Therapeutics

We are dedicated to discovering, developing and delivering cures for intractable and rare diseases.

We are passionate about helping patients lead more hopeful, healthier and happier lives

ASC Therapeutics is

"HERE TO CURE".

ASC Therapeutics is a fully incorporated biopharmaceutical company focusing on the development of curative therapeutic products that are enabled by our proprietary gene editing platform, TARGATT™ and other gene editing technologies developed after 12 years of R&D at Applied Stem Cells, Inc.

The company’s therapeutic development pipeline includes several preclinical stage programs in gene and cell therapy progressing into clinical stage in 2022 focusing on several blood disorders.

Our Pipeline

Discovery

Preclinical

Phase 1/2a

Phase 2b

GVHD

Cell Therapy/phase 2b

Hemophilia A

Gene Therapy

Hemophilia A

Gene Editing

Hemophilia B

Gene Editing

β-Thalassemia

Gene Editing

Undisclosed

Gene editing, Gene/Cell Therapy

Dicscovery

Preclinical

Phase 1/2a

Phase 2b

Hemophilia A

Gene Therapy

Hemophilia A

Gene Editing

Hemophilia B

Gene Editing

β-Thalassemia

Gene Editing

GVHD

Cell Therapy/phase 2B

Undisclosed

Gene editing, Gene/Cell Therapy

Our current pipeline is focused on blood diseases. We are devoted to discovering, developing and delivering cures for intractable diseases using gene and cell therapies.

Not only do we have experienced teams for discovery research, CMC, pre-clinical and clinical development, we also collaborate with leading academic and industry partners around the world to advance and expand our product pipeline. Building upon our deep knowledge in stem cell, gene therapy and genome editing technology, we are devoted to discovering, developing and delivering cures for intractable diseases.

Our Team

Executive Team

ASC Therapeutics is an independent, fully incorporated biopharmaceutical company with dedicated scientists and industry veterans with a strong belief.

Ruhong Jiang, PhD

Co-founder, President and CEO

Oscar Segurado, MD, PhD

Chief Medical Officer

Ruhong Jiang, PhD

Co-founder, President and CEO

Oscar Segurado, MD, PhD

Chief Medical Officer

Gary Potter

Senior VP, Global Operations

Zoya Gluzman-Poltorak, PhD, MBA

VP, Therapeutic Development

Weicheng Wu, PhD, RAC

VP, Global Regulatory Affairs

Terry Brown

Senior Director, Quality

Jeremy Watts

Director, Corporate Program Management

Hemophilia Advisory Board

Mark A. Kay, MD, Ph.D

Dennis Farrey Family Professor in Department of Pediatrics, Professor of Genetics, Stanford University

Kimo Stine, MD

Professor of Pediatrics and Medical Director of the Arkansas Center of Bleeding Disorders at Arkansas Children’s Hospital

Annette Von Drygalski, MD, PharmD, RMSK

Professor of Clinical Medicine, Director of the Hemophilia and Thrombosis Treatment Center at UCSD

Gili Kenet, MD

Professor and chair of the hematology Department at the Sackler Medical School, Tel Aviv University

Steven Pipe, MD, PhD

Professor of Pediatrics and Pathology, Medical Director of the Pediatric Hemophilia and Coagulation Disorders Program at the University of Michigan

Mark A. Kay, MD, Ph.D

Dennis Farrey Family Professor in Department of Pediatrics, Professor of Genetics, Stanford University

Glenn Pierce, MD, PhD

Board Director at the US National Hemophilia Foundation and World Federation of Hemophilia

Annette Von Drygalski, MD, PharmD, RMSK

Professor of Clinical Medicine, Director of the Hemophilia and Thrombosis Treatment Center at UCSD

Gili Kenet, MD

Professor and chair of the hematology Department at the Sackler Medical School, Tel Aviv University

Steven Pipe, MD, PhD

Professor of Pediatrics and Pathology, Medical Director of the Pediatric Hemophilia and Coagulation Disorders Program at the University of Michigan

Cell Therapy Advisory Board

Olle Ringdén, MD, PhD

Professor of Transplantation Immunology, Karolinska Institute

Behnam Sadeghi, MD, PhD

Head of translational cell therapy Research group, Karolinska Institute

John E. Wagner, MD

Director of the Institute for Cell, Gene and Immunotherapy and Member of the BMT Program, University of Minnesota

Robert Negrin, MD

Professor of Medicine and Chief of the Division of Blood and Marrow Transplantation at Stanford University.

Robert Negrin, MD

Professor of Medicine and Chief of the Division of Blood and Marrow Transplantation at Stanford University.

Olle Ringdén, MD, PhD

Professor of Transplantation Immunology, Karolinska Institute

Behnam Sadeghi, MD, PhD

Head of translational cell therapy Research group, Karolinska Institute

John E. Wagner, MD

Director of the Institute for Cell, Gene and Immunotherapy and Member of the BMT Program, University of Minnesota

Maple Syrup Urine Disease Advisory Board

Guangping Gao, PhD

AAV gene therapy pioneer

Kevin Strauss, MD

PI of Zolgensma gene therapy

Guangping Gao, PhD

Biomedical Research, University of Massachusetts Medical School

Guangping Gao, PhD

AAV gene therapy pioneer

Kevin Strauss, MD

PI of Zolgensma gene therapy

Dan Wang, PhD

Biomedical Research, University of Massachusetts Medical School

NEWS & BLOG

New Agreement Set to Scale Up Production of Hem A Gene Therapy

admin June 20, 2022

Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A

admin June 13, 2022